$6.91
0[0.00%]
At close: Apr 22
$6.91
0[0.00%]
PreMarket: 4:20PM EDT
Verve Therapeutics
(NASDAQ:VERV)Verve Therapeutics Stock (NASDAQ:VERV), Analyst Ratings, Price Targets, Predictions
Verve Therapeutics Inc has a consensus price target of $42.75, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from Stifel, RBC Capital, and Cantor Fitzgerald on April 3, 2024, February 28, 2024, and September 13, 2023. With an average price target of $32.33 between Stifel, RBC Capital, and Cantor Fitzgerald, there's an implied 367.92% upside for Verve Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
RBC Capital
Cantor Fitzgerald
Guggenheim
Credit Suisse
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Verve Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | VERV | Buy Now | Verve Therapeutics | $6.91 | 478.87% | Stifel | Dae Gon Ha | $56 → $40 | Maintains | Buy | Get Alert |
| 02/28/2024 | VERV | Buy Now | Verve Therapeutics | $6.91 | 406.51% | RBC Capital | Luca Issi | → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 09/13/2023 | VERV | Buy Now | Verve Therapeutics | $6.91 | 218.38% | Cantor Fitzgerald | Rick Bienkowski | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 08/29/2023 | VERV | Buy Now | Verve Therapeutics | $6.91 | 218.38% | Cantor Fitzgerald | Rick Bienkowski | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 08/15/2023 | VERV | Buy Now | Verve Therapeutics | $6.91 | 695.95% | Guggenheim | Seamus Fernandez | $56 → $55 | Maintains | Buy | Get Alert |
| 08/11/2023 | VERV | Buy Now | Verve Therapeutics | $6.91 | 348.63% | Credit Suisse | Richard Law | → $31 | Reiterates | Neutral → Neutral | Get Alert |
| 06/16/2023 | VERV | Buy Now | Verve Therapeutics | $6.91 | 319.68% | Canaccord Genuity | Whitney Ijem | → $29 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | VERV | Buy Now | Verve Therapeutics | $6.91 | 406.51% | RBC Capital | Luca Issi | → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 04/13/2023 | VERV | Buy Now | Verve Therapeutics | $6.91 | 319.68% | Canaccord Genuity | Whitney Ijem | → $29 | Initiates | → Buy | Get Alert |
| 02/01/2023 | VERV | Buy Now | Verve Therapeutics | $6.91 | 203.91% | Cantor Fitzgerald | Rick Bienkowski | → $21 | Initiates | → Neutral | Get Alert |
| 12/15/2022 | VERV | Buy Now | Verve Therapeutics | $6.91 | 88.13% | Goldman Sachs | Andrea Tan | → $13 | Initiates | → Sell | Get Alert |
| 11/08/2022 | VERV | Buy Now | Verve Therapeutics | $6.91 | 406.51% | RBC Capital | Luca Issi | $42 → $35 | Maintains | Outperform | Get Alert |
| 10/06/2022 | VERV | Buy Now | Verve Therapeutics | $6.91 | 594.65% | Credit Suisse | Richard Law | → $48 | Initiates | → Neutral | Get Alert |
| 08/25/2022 | VERV | Buy Now | Verve Therapeutics | $6.91 | 710.42% | Stifel | Dae Gon Ha | $32 → $56 | Upgrade | Hold → Buy | Get Alert |
| 07/18/2022 | VERV | Buy Now | Verve Therapeutics | $6.91 | 797.25% | BMO Capital | Kostas Biliouris | $48 → $62 | Maintains | Outperform | Get Alert |
| 06/17/2022 | VERV | Buy Now | Verve Therapeutics | $6.91 | 594.65% | BMO Capital | Kostas Biliouris | → $48 | Initiates | → Outperform | Get Alert |
| 02/18/2022 | VERV | Buy Now | Verve Therapeutics | $6.91 | 507.81% | RBC Capital | Luca Issi | → $42 | Initiates | → Outperform | Get Alert |
| 09/24/2021 | VERV | Buy Now | Verve Therapeutics | $6.91 | 739.36% | Stifel | Dae Gon Ha | — | Initiates | → Hold | Get Alert |
| 07/12/2021 | VERV | Buy Now | Verve Therapeutics | $6.91 | 1231.4% | William Blair | Raju Prasad | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Verve Therapeutics (VERV)?
The latest price target for Verve Therapeutics (NASDAQ: VERV) was reported by Stifel on April 3, 2024. The analyst firm set a price target for $40.00 expecting VERV to rise to within 12 months (a possible 478.87% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verve Therapeutics (VERV)?
The latest analyst rating for Verve Therapeutics (NASDAQ: VERV) was provided by Stifel, and Verve Therapeutics maintained their buy rating.
When was the last upgrade for Verve Therapeutics (VERV)?
The last upgrade for Verve Therapeutics Inc happened on August 25, 2022 when Stifel raised their price target to $56. Stifel previously had a hold for Verve Therapeutics Inc.
When was the last downgrade for Verve Therapeutics (VERV)?
There is no last downgrade for Verve Therapeutics.
When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Verve Therapeutics (VERV) correct?
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a maintained with a price target of $56.00 to $40.00. The current price Verve Therapeutics (VERV) is trading at is $6.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.